Katie Tryhane
Stock Analyst at Credit Suisse
(1.98)
# 2,937
Out of 4,735 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $169.81 | +67.83% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $21.77 | +129.67% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $244.11 | +51.57% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.27 | +572.78% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $427.33 | +80.19% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $5.23 | +932.50% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $17.63 | +268.69% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $167.53 | +37.29% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $20.55 | +167.64% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $94.05 | -78.73% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $573.06 | -14.49% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $228.00 | +125.88% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $205.07 | +14.60% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $169.81
Upside: +67.83%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $21.77
Upside: +129.67%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $244.11
Upside: +51.57%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.27
Upside: +572.78%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $427.33
Upside: +80.19%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $5.23
Upside: +932.50%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $17.63
Upside: +268.69%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $167.53
Upside: +37.29%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $20.55
Upside: +167.64%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $94.05
Upside: -78.73%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $573.06
Upside: -14.49%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $228.00
Upside: +125.88%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $205.07
Upside: +14.60%